Biogen shares fell after a mid-stage trial of its Alzheimer's drug diranersen failed to show convincing evidence of benefit, with only hints of improvement in some areas.
bloomberg-industries07/14, 09:44 PM
Related assets
Coming up for BIIB
Explore next
Latest BIIB news
Finnhub07/30, 06:43 AM
Biogen published its second-quarter results on Wednesday morning.
Bloomberg07/29, 06:35 PM
WSJ07/29, 05:23 PM
Biogen cut its full-year adjusted earnings forecast after second-quarter profit declined.